Sotagliflozin

CHEMBL3039507 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

424.9 g/mol

LogP

3.2

Phase

4

Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

الوزن الجزيئي

424,9000 g/mol

LogP

3,20

TPSA

104,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1

InChI

InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1

Molecular Formula

C21H25ClO5S

HBD / HBA

3 / 6

الروابط القابلة للدوران

6

الذرات الثقيلة

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

Yes, Sotagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039507. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24831714. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Sotagliflozin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C21H25ClO5S
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.